**Name of Journal:** *World Journal of Clinical Infectious Diseases*

**Manuscript NO:** 57710

**Manuscript Type:** CASE REPORT

***Stenotrophomonas maltophilia*,** **an emerging pathogen in newborns: Three case reports** **and a review of the literature**

Behera B. *S. maltophilia*,an emerging pathogen in newborns

**Bijaylaxmi Behera,** Department of Pediatrics &Neonatology, Chaitanya Hospital, Chandigarh 160044, India

**Author contributions:** Behera B managed the patients, performed the literature search, and wrote the manuscript.

**Corresponding author: Bijaylaxmi Behera, MD, Chief Physician,** Department of Pediatrics &Neonatology, Chaitanya Hospital, Sector 44, Chandigarh 160044, India. jollybubu2008@gmail.com

**Received:** June 20, 2020

**Revised:** November 5, 2020

**Accepted:** December 2, 2020

**Published online:**

**Abstract**

BACKGROUND

*Stenotrophomonas maltophilia* (*S. maltophilia*)is a rare cause of neonatal sepsis with significant morbidity and mortality and has extensive resistance to several antibiotics leaving few options for antimicrobial therapy. Only a few cases have been reported in neonates from developing countries. We report three cases of critically ill, extramural babies with neonatal *S. maltophilia* sepsis. All three babies recovered and were discharged.

CASE SUMMARY

All three cases were term extramural babies, who were critically ill at the time of presentation at our neonatal intensive care unit. They had features of multiorgan dysfunction at admission. Blood culture was positive for *S. maltophilia* in two babies and one had a positive tracheal aspirate culture. The babies were treated according to the antibiogram available. They recovered and were subsequently discharged.

CONCLUSION

Although various authors have reported *S. maltophilia* in pediatric and adult populations, only a few cases have been reported in the newborn period and this infection is even rarer in developing countries. Although *S. maltophilia* infection has a grave outcome, our three babies were successfully treated and subsequently discharged**.**

**Key Words:** Ceftriaxone; Multidrug resistant; Neonatal sepsis; *Stenotrophomonas maltophilia*; Cotrimoxazole; Tigecycline

Behera B. *Stenotrophomonas maltophilia*, an emerging pathogen in newborns: Three case reports and a review of the literature. *World J Clin Infect Dis* 2020; In press

**Core Tip:** *Stenotrophomonas maltophilia* is a rare cause of neonatal sepsis with significant morbidity and mortality and has extensive resistance to several antibiotics leaving few options for antimicrobial therapy. Although there have been reports in the adult population, only a few cases have been reported in neonates from developing countries. The majority of babies have succumbed to this deadly infection. We present three cases of out-born babies with neonatal sepsis, who were critically ill. All three babies recovered and were subsequently discharged.

**INTRODUCTION**

*Stenotrophomonas maltophilia* (*S. maltophilia*) was previously known as *Pseudomonas maltophilia* or *Xanthomonas maltophilia*[1]. It is currently an important multi-drug resistant, gram-negative, oxidase-negative, and catalase-positive, non-fermenting nosocomial pathogen associated with significant mortality[1]. *S. maltophilia* is the only species of *Stenotrophomonas* known to infect humans. It ranks third amongst the four most common pathogenic non-fermenting *Gram negative bacilli* (*NFGNBs*), the others being *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Burkholderia cepacia* complex[2]. *S. maltophilia* may have varied manifestations such as bacteremia, pneumonia, urinary tract infection, meningitis, endocarditis *etc*[3]. It is found in water, sewage, soil, plants, animals and in hospital settings, and may also be isolated from washbasins, respirators, antiseptics, and medical devices leading to device-associated infections such as catheter-associated bloodstream infections, urinary tract infections, and ventilator-associated pneumonia[4,5]. The treatment of *S. maltophilia* infection is very difficult as it is intrinsically resistant to the majority of commonly used drugs, such as all Carbapenems, and Levofloxacin[6-9]. Strains are usually susceptible to Trimethoprim-Sulfamethoxazole, but this combination is not used in neonates due to adverse effects. Strains have variable susceptibility to Ceftazidime[6,7]. *S. maltophilia* has a contrasting antibiotic susceptibility pattern to other *NFGNBs* such as *A. baumannii*, *P. aeruginosa* and *Burkholderia cepacia*, and the correct identification of *S. maltophilia* is very important, as it has to be differentiated from these other organisms. However, it is very challenging for a routine laboratory to identify *S. maltophilia*, due to its inert biochemical profile and difficulty in the interpretation of phenotypic characteristics. Subsequently, its correct identification is essential as no single drug is effective against all *NFGNBs*, which hinders initiation of appropriate empirical treatment resulting in increased morbidity and mortality[10].

**CASE PRESENTATION**

***Case 1***

**Chief complaints:** An out-born baby, delivered to a primigravida mother at 38 wk, with a birth weight of 3000 g *via* a lower segment caesarean section (LSCS) due to fetal distress, cried immediately after birth, but developed severe respiratory distress in the form of retractions and grunting with pulse oxygen saturation of 84%.

**History of present illness**: The baby was started on oxygen by hood, and received intravenous fluids, Cefotaxime, Amikacin and Vitamin K. On day two of life, the baby’s respiratory distress worsened with chest X-ray suggestive of right lung pneumothorax and was referred to our hospital.

**Physical examination**: On admission, the baby had severe respiratory distress with a Downes score of 6/10 and features of shock such as weak pulse, prolonged capillary refill time (CFT), heart rate (HR) of 190 bpm, blood pressure (BP) of 40/28 mmHg and peripheral oxygen saturation (SpO2) of 82%. Right side air entry was decreased compared to the left side.

**Laboratory examinations:** A sepsis screen sent on admission was positive with procalcitonin (PCT) of 15.43 ng/ml, µESR of 12 mm, total leucocyte count (TLC) of 20300 and an IT ratio of 0.22. Blood culture sent on admission showed growth of *S. maltophilia* (multi-drug resistant) (Table 1). Lumbar puncture (LP) was negative for meningitis.

**Imaging examinations:**Imaging showedright lung pneumothorax with left side consolidation.

***Case 2***

**Chief complaints:** A term, 37 wk out-born baby, weighing 2600 g, delivered by LSCS due to previous LSCS, cried immediately after birth but developed respiratory distress soon after birth.

**History of present illness**: The baby was started on oxygen and *i.v*. antibiotics. On day three of life, the baby’s respiratory distress worsened and the child was referred to our hospital.

**Physical examination**: On admission, the child had severe respiratory distress with a Downes score of 7/10 and had features of poor perfusion such as tachycardia (HR: 185/min), CFT of more than 3 s, extremely weak pulse and unrecordable BP and SpO2.

**Laboratory examinations:** A sepsis screen sent on admission was positive with PCT of 25.3 ng/mL, µESR of 10 mm, TLC was 21200, platelet count was 44000 and IT ratio was 0.22. Prothrombin time (PT) was 22 s, INR was 1.8 and partial activated partial thromboplastin time (aPTT) was 64 s. Blood culture sent on admission grew *S. maltophilia*, and the sensitivity pattern is provided in Table 1. LP was negative for meningitis.

**Imaging examinations:** Chest X-ray on admission was suggestive of white out lungs.

***Case 3***

**Chief complaints:** A term 38 wk out-born baby boy was referred to our hospital with symptomatic hypoglycemia and respiratory failure.

**History of present illness**: A term 38 wk 2600 g, out-born male baby was delivered by LSCS due to non-progression of labor, to a 25-year-old primigravida mother who was leaking per vagina for 20 h. Antenatal history was uneventful. The child developed symptomatic hypoglycemia at 10 h of life with lethargy and one episode of seizures. A sepsis screen revealed C-reactive protein of 10.9 mg/L and the baby was started on Cefotaxime and Amikacin. He developed severe respiratory distress on day four of life and was intubated and then referred to our hospital on manual ventilation.

**Physical examination**: On admission, the baby was in shock with prolonged CFT, tachycardia (HR: 192/min, weak pulse, BP of 36/22 mmHg), posturing, and a SpO2 of 95% on manual ventilation.

**Laboratory examinations:** A sepsis screen revealed PCT of 16 ng/mL, µESR was 12 mm and IT ratio was 0.20, platelet count was 23000 with a deranged coagulogram (PT: 29 s, INR: 2, aPTT: 78 s). Arterial blood gas revealed mild metabolic acidosis. Blood culture isolated *Staphylococcus epidermidis*; which was sensitive to Cotrimoxazole, Nitrofurantoin, Linezolid, Daptomycin, Teicoplanin and Vancomycin. Tracheal aspirate sent on admission grew *S. maltophilia* which was sensitive to Ceftriaxone and had intermediate sensitivity to Colistin, Aztreonam, Ceftazidime, Moxifloxacin and was resistant to Ampicillin, Amikacin, Gentamicin, Cefotaxime, Cefepime, Meropenem, Augmentin, Cefuroxime, Cefoxitin, Ciprofloxacin, Levofloxacin and Cotrimoxazole (Table 1).

**Imaging examinations:** Chest X-ray was suggestive of pneumonia. Cranial ultrasonography was suggestive of cerebral edema with chinked ventricles.

**FINAL DIAGNOSIS**

***Case 1***

Term/38 wk/AGA/*S. maltophilia* sepsis/septic shock/pneumonia/right side pneumothorax.

***Case 2***

Term/37 wk/AGA/*S. maltophilia* sepsis/septic shock/pneumonia/disseminated intravascular coagulation (DIC)/pulmonary arterial hypertension (PAH).

***Case 3***

Term/38 wk/AGA/*Staphylococcus epidermidis* and *S. maltophilia* sepsis/septic shock/pneumonia/meningitis/DIC.

**TREATMENT**

***Case 1***

On admission, the baby had severe respiratory distress with a Downes score of 6/10 and features of shock. The child was intubated and was started on synchronized intermittent mandatory ventilation (SIMV) mode with settings of 13/04/60/100% and a pneumothorax was drained using an intercostal drainage tube. A normal saline bolus was followed by ionotropic support with Dopamine and Adrenaline and *i.v*. antibiotics Vancomycin and Meropenem were started. Colistin was added on day three after admission, as there was no significant clinical improvement. On the fourth day of life, the chest tube was clamped and removed. The baby was extubated on day five of NIMV mode with settings of 16/05/40/21% and gradually changed to nasal continuous positive airway pressure (CPAP). Subsequently, the baby was weaned to nasal prongs and finally oxygen support was stopped on the eighth day of life. Vancomycin, Meropenem and Colistin were given for a total duration of 14 d. Ionotropes were slowly tapered and finally stopped on day five of life. The baby was started on measured tube feeding and then gradually to spoon feeding and breastfeeding by day ten of life.

***Case 2***

A term, 37 wk out-born baby, weighing 2600 g, delivered by LSCS due to previous LSCS, cried immediately after birth but developed respiratory distress soon after birth and was started on oxygen and *i.v.* antibiotics. On day three of life, respiratory distress worsened and the baby was referred to our hospital. On admission, the child had severe respiratory distress with a Downes score of 7/10 and was in shock, the child was intubated and started on conventional ventilation but was changed to high frequency ventilation with a maximum setting of mean airway pressure of 18, inspired oxygen fraction of 100%, DP of 60, frequency-10 and required maximum inotropic support of Dopamine 20, Dobutamine 20, Adrenaline 0.5, and Milrinone 0.2 μg/kg/min. A chest X-ray on admission was suggestive of white out lungs; therefore, the baby was given surfactant and within 24 h was changed to conventional ventilation (SIMV mode 18/5/50/50%). The baby also had PAH and was given Sildenafil by injection. Meropenem and Vancomycin were also administered. Colistin injection was added on day three after admission due to worsening clinical condition with shock and DIC. In addition to DIC, the baby also had thrombocytopenia, coagulopathy manifesting as orogastric and ET bleeding and received multiple platelet, fresh frozen plasma and packed red blood cell transfusions. The ventilator setting was gradually tapered and the baby was extubated to NIMV mode on the twelfth day after admission, and changed to nasal CPAP by day fifteen after admission and off oxygen by day seventeen. Blood culture sent on admission grew *S. maltophilia* with sensitivity to Tigecycline which was added and Colistin continued. The baby received Vancomycin for seven days plus Tigecycline and Colistin for fourteen days. Tube feeding was started on day six of life and gradually increased to full feeding by day eleven after admission. The baby was subsequently breastfed.

***Case 3***

The baby required ionotropic support with Dopamine, Adrenaline and intravenous fluids and was started on SIMV mode (18/6/45/50%). A sepsis screen was sent and the child was started on Meropenem, Vancomycin and Colistin. As the baby was critically ill and did not show an improvement in symptoms, Ceftriaxone was started and Meropenem was discontinued on day three after admission, as soon as the tracheal aspirate report was received. CSF analysis was performed after the platelet count had improved, which was suggestive of meningitis. The child received fresh frozen plasma and platelet transfusions for DIC. Ionotropic support was gradually tapered and then stopped by day seven after admission and tube feeding was started. The baby’s sensorium and spontaneous efforts improved and he was extubated on the eleventh day after admission and changed to NIMV mode (16/6/50/30%). He was subsequently weaned off to CPAP by day fourteen. He was gradually weaned off CPAP by day sixteen and oxygen by day eighteen. Intravenous antibiotics were administered for 21 d, and he received full tube feeding by day twelve after admission and direct oral feeding by day sixteen.

**OUTCOME AND FOLLOW-UP**

***Case 1***

The baby was discharged from hospital on day fifteen of life, was being breastfed and had normal neurological status. At follow-up, the baby was being breastfed and was neurologically normal.

***Case 2***

The baby was discharged after eighteen days of hospitalization. At follow-up, the baby was being breastfed and was healthy.

***Case 3***

The baby was discharged after almost twenty two days of hospitalization on full feeds. At follow-up, the baby was neurologically normal, on mixed feeds and repeat cranial ultrasound was normal.

**DISCUSSION**

*S. maltophilia* is currently an emerging multi-drug resistant, opportunistic pathogen in both hospital and community settings. Studies have shown various risk factors for infection or colonization by *S. maltophilia*, including prior use of broad-spectrum antimicrobial agents such as Carbapenem, Ampicillin, Gentamicin, Vancomycin, Metronidazole, Piperacillin, Cefotaxime, Ceftazidime, Ciprofloxacin, Tobramycin, and Cefepime, and other drugs such as corticosteroids, cytotoxic chemotherapy, immunosuppressive therapy, H2 blockers, and parenteral nutrition[11-16]. Prolonged hospital stay, invasive procedures including mechanical ventilation, intubation, urinary catheterization, central venous catheterization, lower gestational age and low birth weight, neutropenia, underlying diseases such as hepatobiliary, chronic pulmonary, and cardiovascular diseases, organ transplantation, dialysis, intravenous drug use, and human immunodeficiency virus infection, malignancy, and exposure to patients with *S. maltophilia* wound infection were significantly associated with *S. maltophilia* infections[17-21]. In our patients we found that intensive care unit (ICU) stay, administration of broad spectrum antibiotics, and invasive procedures would have contributed to infection with this organism. Although according to the literature, premature and low birth weight babies are more prone to developing this infection, all our cases were term and with good birth weights[21].

According to Jia *et al*[7], maximum isolation of *S. maltophilia* was from respiratory specimens, whereas Abdel-Aziz *et al*[6], reported maximum isolation from urine samples followed by swabs and blood. In our cases, *S. maltophilia* was isolated from blood in the first two cases and from tracheal aspirate in the third case. The identification and antimicrobial susceptibility testing was carried out using VITEK and the results were confirmed with manual MIC calculations.

*S. maltophilia* has several resistance mechanisms to various antibiotic classes such as beta-lactams due to two inducible beta-lactamases, a zinc-containing penicillinase (L1) and a cephalosporinase (L2), an aminoglycoside acetyl-transferase that confers resistance to aminoglycoside antibiotics, and temperature-dependent changes in the outer membrane lipopolysaccharide structure confers added resistance to aminoglycoside antibiotics and possesses efflux pumps[22,23]. Although according to previous reports the organism is resistant to the majority of commonly used drugs such as all Carbapenems and Levofloxacin, and is susceptible to Trimethoprim-Sulfamethoxazole, with variable susceptibility to Ceftazidime[6-9], in our cases except for one, which was sensitive to Ceftazidime and the others were sensitive to Ceftriaxone, all were resistant to Aminoglycosides, Carbapenems, and Cephalosporins. Of the three cases, one was resistant, one was sensitive and one had intermediate sensitivity to Colistin. The first and second cases were sensitive to Tigecycline and in the third case sensitivity was not tested. Two cases were sensitive to Levofloxacin and one was resistant. One case was sensitive to Trimethoprim-Sulfamethoxazole and two were resistant. We administered Colistin and Tigecycline to our patients. In the third case we administered Ceftriaxone, as the organism had intermediate sensitivity to Colistin and Tigecycline sensitivity was not performed. The same baby was monitored for serum bilirubin levels and for other adverse effects. As shown in the literature, Ceftriaxone can be used in neonates and is contraindicated in babies at risk of developing unconjugated hyperbilirubinemia and concurrent administration with calcium[24-26]. In our third case, although tracheal aspirate was positive for *S. maltophilia*, the baby was treated according to the antibiogram, as clinical features were consistent with the infection. However, most clinicians are reluctant to treat this pathogen, when isolated from tracheal aspirate and often treat it as colonization rather than a pathogen[27]. Antibiograms of the three patients are shown in Table 1.

Most infections caused by *S. maltophilia* are associated with severe morbidity and long-term, extensive ICU treatment. According to previous reports, the mortality rates vary between 14%-62%[28,29]. Our three babies were discharged on full feeds with a hospital stay of 14 to 21 d.

**CONCLUSION**

Various case studies on *S. maltophilia* infections in India, such as *S. maltophilia* endophthalmitis[29], tropical pyomyositis[30], unilateral conjunctival ulcer[31], non‑healing leg ulcer[32] and meningitis[33], have been reported in pediatric and adult patients and the isolation rate of *S. maltophilia* was found to be 2.5% (5 isolates) out of 193 *NFGNBs* in various clinical samples[34]. However, neonatal sepsis due to *S. maltophilia* has been reported only by Viswanathan *et al*[1] and Soren *et al*[35]. Here we report three cases of neonatal sepsis due to *S. maltophilia* along with their antibiograms Although *S. maltophilia* infection has a grave outcome our three out-born babies were successfully treated and discharged**.**

**REFERENCES**

1 **Viswanathan R**, Singh AK, Ghosh C, Basu S. Stenotrophomonas maltophilia causing early onset neonatal sepsis. *Indian Pediatr* 2011; **48**: 397-399 [PMID: 21654005 DOI: 10.1007/s13312-011-0063-4]

2 **LiPuma JJ,** CB, Lum GD, Vandamme PA.Burkholderia, Stenotrophomonas, Ralstonia, Cupriavidus, Pandoraea,Brevundimonas, Comamonas and Acidovorax. In: Murray PR,Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of Clinical Microbiology. 9th ed. Ch. 9. Washington, D.C.: ASM Press;2007. p. 749‑69.

3 **Das T**, Deshmukh HS, Mathai A, Reddy AK. Stenotrophomonas maltophilia endogenous endophthalmitis: clinical presentation, sensitivity spectrum and management. *J Med Microbiol* 2009; **58**: 837-838 [PMID: 19429764 DOI: 10.1099/jmm.0.009431-0]

4 **Cheong HS**, Lee JA, Kang CI, Chung DR, Peck KR, Kim ES, Lee JS, Son JS, Lee NY, Song JH. Risk factors for mortality and clinical implications of catheter-related infections in patients with bacteraemia caused by Stenotrophomonas maltophilia. *Int J Antimicrob Agents* 2008; **32**: 538-540 [PMID: 18715768 DOI: 10.1016/j.ijantimicag.2008.05.011]

5 **Verweij PE**, Meis JF, Christmann V, Van der Bor M, Melchers WJ, Hilderink BG, Voss A. Nosocomial outbreak of colonization and infection with Stenotrophomonas maltophilia in preterm infants associated with contaminated tap water. *Epidemiol Infect* 1998; **120**: 251-256 [PMID: 9692603 DOI: 10.1017/s0950268898008735]

6 **Abdel-Aziz N,** Morsy MMF, Amin SS, Mohammed KI, Alharbi AE, Alshami I. Threatening problem of Stenotrophomonas maltophilia producing extended-spectrum betalactamases: Prevalence and automated antibiotic susceptibility pattern. *ClinMicrobial* 2013; **2**: 108 [DOI: 10.4172/2327-5073.1000108]

7 **Jia W**, Wang J, Xu H, Li G. Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms. *Int J Environ Res Public Health* 2015; **12**: 5177-5195 [PMID: 25985315 DOI: 10.3390/ijerph120505177]

8 **Nicodemo AC**, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. *Eur J Clin Microbiol Infect Dis* 2007; **26**: 229-237 [PMID: 17334747 DOI: 10.1007/s10096-007-0279-3]

9 **Waters V**. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas. *Curr Pharm Des* 2012; **18**: 696-725 [PMID: 22229574 DOI: 10.2174/138161212799315939]

10 **Singhal L**, Kaur P, Gautam V. *Stenotrophomonas maltophilia*: From trivial to grievous. *Indian J Med Microbiol* 2017; **35**: 469-479 [PMID: 29405136 DOI: 10.4103/ijmm.IJMM\_16\_430]

11 **Denton M**, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. *Clin Microbiol Rev* 1998; **11**: 57-80 [PMID: 9457429]

12 **Waters VJ,** Go´mez MI, Soong G, Amin S, Ernst RK, Prince A. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. *Infect Immun* 2007; **75**: 1698-1703 [PMID: 17220304 DOI: 10.1128/IAI.01469-06]

13 **Kagen J**, Zaoutis TE, McGowan KL, Luan X, Shah SS. Bloodstream infection caused by Stenotrophomonas maltophilia in children. *Pediatr Infect Dis J* 2007; **26**: 508-512 [PMID: 17529868 DOI: 10.1097/INF.0b013e318059c285]

14 **Ladhani S**, Gransden W. Septicaemia due to glucose non-fermenting, gram-negative bacilli other than Pseudomonas aeruginosa in children. *Acta Paediatr* 2002; **91**: 303-306 [PMID: 12022303 DOI: 10.1080/08035250252833969]

15 **Sattler CA**, Mason EO Jr, Kaplan SL. Nonrespiratory Stenotrophomonas maltophilia infection at a children's hospital. *Clin Infect Dis* 2000; **31**: 1321-1330 [PMID: 11095997 DOI: 10.1086/317473]

16 **del Toro MD**, Rodríguez-Bano J, Herrero M, Rivero A, García-Ordoñez MA, Corzo J, Pérez-Cano R; Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. *Medicine (Baltimore)* 2002; **81**: 228-239 [PMID: 11997719 DOI: 10.1097/00005792-200205000-00006]

17 **Nseir S**, Di Pompeo C, Brisson H, Dewavrin F, Tissier S, Diarra M, Boulo M, Durocher A. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. *Crit Care* 2006; **10**: R143 [PMID: 17026755 DOI: 10.1186/cc5063]

18 **Pathmanathan A**, Waterer GW. Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. *Eur Respir J* 2005; **25**: 911-914 [PMID: 15863651 DOI: 10.1183/09031936.05.00096704]

19 **VanCouwenberghe CJ**, Farver TB, Cohen SH. Risk factors associated with isolation of Stenotrophomonas (Xanthomonas) maltophilia in clinical specimens. *Infect Control Hosp Epidemiol* 1997; **18**: 316-321 [PMID: 9154473 DOI: 10.1086/647618]

20 **Hanes SD**, Demirkan K, Tolley E, Boucher BA, Croce MA, Wood GC, Fabian TC. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. *Clin Infect Dis* 2002; **35**: 228-235 [PMID: 12115086 DOI: 10.1086/341022]

21 **Mutlu M**, Yılmaz G, Aslan Y, Bayramoğlu G. Risk factors and clinical characteristics of Stenotrophomonas maltophilia infections in neonates. *J Microbiol Immunol Infect* 2011; **44**: 467-472 [PMID: 21606009 DOI: 10.1016/j.jmii.2011.04.014]

22 **Avison MB**, Higgins CS, von Heldreich CJ, Bennett PM, Walsh TR. Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia. *Antimicrob Agents Chemother* 2001; **45**: 413-419 [PMID: 11158734 DOI: 10.1128/AAC.45.2.413-419.2001]

23 **Spencer RC**. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. *J Hosp Infect* 1995; **30 Suppl**: 453-464 [PMID: 7560984 DOI: 10.1016/0195-6701(95)90049-7]

24 **WHO.** Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines: Geneva, 29 September to 3 October 2008

25 Pacifici GM. Clinical Pharmacology of Ceftriaxone in Infants and Children. J Target Drug Deliv Volume 3(1): 2019

26 **Bradley JS**, Wassel RT, Lee L, Nambiar S. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. *Pediatrics* 2009; **123**: e609-e613 [PMID: 19289450 DOI: 10.1542/peds.2008-3080]

27 **Tillman EM,** Firmani SE, Ackerman VL, Slaven JE, Cristea AI. Evaluation of the Treatment of Stenotrophomonas maltophilia in Tracheostomy-Dependent Pediatric Patients. *J Pediatr Pharmacol Ther* 2019; **24**: 510-516 [PMID: 31719813 DOI: 10.5863/1551-6776-24.6.510]

28 **Wang YL,** Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. *Antimicrob Agents Chemother* 2014; **58**: 176-182 [PMID: 24145530 DOI: 10.1128/AAC.01324-13]

29 **Nayyar C,** Thakur P, Tak V, Saigal K. Stenotrophomonas maltophilia: An Emerging Pathogen in Paediatric Population. *J Clin Diagn Res* 2017; **11**: DC08-DC11 [PMID: 28273966 DOI: 10.7860/JCDR/2017/24304.9318]

30 **Thomas J**, Prabhu VN, Varaprasad IR, Agrawal S, Narsimulu G. Stenotrophomonas maltophilia: a very rare cause of tropical pyomyositis. *Int J Rheum Dis* 2010; **13**: 89-90 [PMID: 20374391 DOI: 10.1111/j.1756-185X.2009.01447.x]

31 **Mahendradas P**, Avadhani K, Anandula V, Shetty R. Unilateral conjunctival ulcer due to Stenotrophomonas maltophilia infection. *Indian J Ophthalmol* 2012; **60**: 134-136 [PMID: 22446910 DOI: 10.4103/0301-4738.94056]

32 **Nag F**, De A, Banerjee K, Chatterjee G. Non healing leg ulcer infected with Stenotrophomonas maltophilia: first reported case from India. *Int Wound J* 2013; **10**: 356-358 [PMID: 22289105 DOI: 10.1111/j.1742-481X.2012.00938.x]

33 **Sood S**, Vaid VK, Bhartiya H. Meningitis due to Stenotrophomonas maltophilia after a Neurosurgical Procedure. *J Clin Diagn Res* 2013; **7**: 1696-1697 [PMID: 24086879 DOI: 10.7860/JCDR/2013/5614.3248]

34 **Malini A**, Deepa E, Gokul B, Prasad S. Nonfermenting gram-negative bacilli infections in a tertiary care hospital in kolar, karnataka. *J Lab Physicians* 2009; **1**: 62-66 [PMID: 21938252 DOI: 10.4103/0974-2727.59701]

35 **Soren C,** Jagtap S, Malathi V, Aparnadevi L. Stenotrophomonas maltophilia: a rare cause of early onset neonatal sepsis. *Int J Contemp Pediatr* 2018; **5**: 2006-2007 [DOI: 10.18203/2349-3291.ijcp20183548]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patients’ guardians for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict-of-interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** June 20, 2020

**First decision:** October 21, 2020

**Article in press:**

**Specialty type:** Infectious diseases

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Tillman EM **S-Editor:** Zhang H **L-Editor:** Webster JR **P-Editor:**

**Table 1 Antibiograms of the three cases included in this report**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Case No.** | **Cefotaxime** | **Ceftriaxone** | **Cefepime** | **Ceftazidime** | **Cefu** | **Amik** | **Gent** | **Amp** | **Mero** | **Cipro** | **Levo** | **Moxi** | **Amox** | **S-T** | **Colis** | **Tigecy** | **Aztreo** |
| 1 | R | R | R | R | R | R | R | R | R | R | S | R | R | R | S | T | R |
| 2 | R | R | R | S | R | R | R | R | R | S | S | S | R | S | R | S | NA |
| 3 | R | S | R | IS | R | R | R | R | R | R | R | IS | R | R | IS | NA | IS |

Cefu: Cefuroxime; Amik: Amikacin; Gent: Gentamicin; Amp: Ampicillin; Mero: Meropenem; Cipro: Ciprofloxacin; Levo: Levofloxacin; Moxi: Moxifloxacin; Amox: Amoxicillin; S-T: Sulfamethoxazole-trimethoprim; Tigecy: Tigecycline; Aztreo: Aztreonam.